Search
Now showing items 1-10 of 26
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
(2020-02-24)
AIMS: To examine the association between socioeconomic status (SES) and disease-modifying therapy (DMT) prescribing patterns in people with relapsing-remitting multiple sclerosis (pwRRMS). METHODS: A cross-sectional analysis ...
SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
(Wiley Online, 2020-05-08)
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic1 is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of ...
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
(Elsevier, 2020-10-23)
Background
There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance ...
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
(2020-12)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020